Alembic Pharmaceuticals Ltd
NSE:APLLTD

Watchlist Manager
Alembic Pharmaceuticals Ltd Logo
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Watchlist
Price: 1 035.45 INR -0.93%
Market Cap: 203.5B INR
Have any thoughts about
Alembic Pharmaceuticals Ltd?
Write Note

Alembic Pharmaceuticals Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Alembic Pharmaceuticals Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Pre-Tax Income
â‚ą7B
CAGR 3-Years
-11%
CAGR 5-Years
-3%
CAGR 10-Years
7%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Pre-Tax Income
â‚ą72.3B
CAGR 3-Years
35%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Pre-Tax Income
â‚ą61.3B
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
15%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Pre-Tax Income
â‚ą128.4B
CAGR 3-Years
22%
CAGR 5-Years
18%
CAGR 10-Years
5%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Pre-Tax Income
â‚ą25.8B
CAGR 3-Years
15%
CAGR 5-Years
30%
CAGR 10-Years
9%
M
Mankind Pharma Ltd
NSE:MANKIND
Pre-Tax Income
â‚ą24B
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Alembic Pharmaceuticals Ltd
Glance View

Market Cap
203.5B INR
Industry
Pharmaceuticals

Alembic Pharmaceuticals Ltd., with roots tracing back over a hundred years, began as a modest tincture and alcohol company in Vadodara, India. Its journey from crafting everyday remedies to becoming a stalwart in the pharmaceutical industry exemplifies ambition intertwined with tradition. Today, Alembic stands as a formidable entity, specializing in the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs) and generic formulations. The company thrives on a blend of innovation and scalability, strategically advancing its manufacturing capabilities while adhering to stringent quality standards. This commitment has not only bolstered its domestic stronghold but also enabled it to penetrate highly regulated international markets, such as the United States and Europe. The company's revenue model is anchored on an extensive portfolio that addresses therapeutic areas ranging from cardiovascular and anti-diabetics to respiratory and anti-infective products. By leveraging its robust R&D infrastructure, Alembic consistently introduces new and complex generics, amplifying its offerings while navigating the generic drug pricing pressures. Their vertically integrated operations ensure cost efficiency and control over API supplies, easing supply chain constraints and fortifying their competitive position. Additionally, strategic partnerships and investments in advanced manufacturing technologies have augmented its capability to meet global demands, cementing Alembic’s reputation as a reliable partner in the pharmaceutical landscape. This multifaceted approach not only expands its business horizons but firmly establishes Alembic as a key player in addressing global healthcare needs.

APLLTD Intrinsic Value
963.73 INR
Overvaluation 7%
Intrinsic Value
Price

See Also

What is Alembic Pharmaceuticals Ltd's Pre-Tax Income?
Pre-Tax Income
7B INR

Based on the financial report for Sep 30, 2024, Alembic Pharmaceuticals Ltd's Pre-Tax Income amounts to 7B INR.

What is Alembic Pharmaceuticals Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
7%

Over the last year, the Pre-Tax Income growth was 27%. The average annual Pre-Tax Income growth rates for Alembic Pharmaceuticals Ltd have been -11% over the past three years , -3% over the past five years , and 7% over the past ten years .

Back to Top